|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1999-5-20
|
|
pubmed:abstractText |
Donepezil is a new drug recently approved in the United States and Canada for the treatment of Alzheimer's disease (AD). We estimated the cost-effectiveness of donepezil 5 mg daily as an adjunct to usual care in the management of persons with mild-to-moderate AD defined as a Mini-Mental Health State Examination (MMSE) score in the range 10 to 26.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0002-8614
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
570-8
|
|
pubmed:dateRevised |
2008-3-10
|
|
pubmed:meshHeading |
pubmed-meshheading:10323651-Aged,
pubmed-meshheading:10323651-Alzheimer Disease,
pubmed-meshheading:10323651-Canada,
pubmed-meshheading:10323651-Cholinesterase Inhibitors,
pubmed-meshheading:10323651-Cost-Benefit Analysis,
pubmed-meshheading:10323651-Decision Support Techniques,
pubmed-meshheading:10323651-Humans,
pubmed-meshheading:10323651-Indans,
pubmed-meshheading:10323651-Markov Chains,
pubmed-meshheading:10323651-Mental Status Schedule,
pubmed-meshheading:10323651-Piperidines
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
|
|
pubmed:affiliation |
Department of Clinical Epidemiology & Biostatistics, McMaster University, St. Joseph's Hospital, Hamilton, Ontario.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
